Molecule News and Research

RSS

454 Life Sciences and DNA Electronics partner to develop high-throughput DNA sequencing system

454 Life Sciences, a Roche Company, announced today that it has entered an exclusive partnership with DNA Electronics for the development of a low-cost, high-throughput DNA sequencing system. As part of the agreement, Roche has signed a non-exclusive license for relevant IP from DNA Electronics' proprietary semiconductor technology portfolio, which enables sensitive detection of nucleotide incorporation during sequencing.

1 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010

Mechanism of rogue cell killer discovered

A team of Melbourne and London researchers have shown how a protein called perforin punches holes in, and kills, rogue cells in our bodies. Their discovery of the mechanism of this assassin is published today in the science journal Nature.

1 Nov 2010

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

Scientists from the UK and Australia have seen the human immune system's assassin a protein called perforin in action for the first time. The UK team, funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Wellcome Trust, is based at Birkbeck College where they used powerful electron microscopes to study the mechanism that perforin uses to punch holes in rogue cells.

1 Nov 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Compugen signs oncology research collaboration agreement with Seattle Genetics

Compugen Ltd. announced today that it has signed a research collaboration agreement with Seattle Genetics, Inc., USA, covering a Compugen-discovered oncology target. The agreement provides Seattle Genetics with an initial evaluation period and an option for an exclusive worldwide milestone and royalty bearing license for development and commercialization of monoclonal antibody therapeutics addressing this novel target.

29 Oct 2010

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Mechanism that controls embryonic development could also prevent cancer

Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

New findings on Th17 cells pave way for human cancer treatment protocol

A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

29 Oct 2010

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.

29 Oct 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Richmont establishes distribution of PURE's SDC-based IV-7 products in Middle East

PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its marketing partner, Richmont Sciences (Richmont), has established distribution of PURE's SDC-based IV-7™ products in the Middle East region. Under this arrangement, PURE sells IV-7 products to Richmont for resale into the Middle East, where the IV-7 water treatment and disinfection products have been registered by the United Arab Emirates-Dubai Municipality. Richmont is initially focusing on distribution of IV-7 Water Treatment™.

28 Oct 2010

Immune system may play a role in cancer therapies: Study

The immune system may play a critical role in ensuring the success of certain types of cancer therapies, according to a new study by researchers at the Stanford University School of Medicine. The research showed treatments that disable cancer-promoting genes called oncogenes are much more successful in eradicating tumors in the presence of a signaling molecule secreted by kind of immune cell called a T helper cell.

28 Oct 2010

The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

The Methodist Hospital Research Institute® (TMHRI) today opened a 12-story, 440,000 square foot research facility dedicated solely to research and equipped with the world's most advanced technology to help research scientists, physicians and engineers cure diseases that afflict today's patients.

28 Oct 2010

Scientists suggest E-cadherin can function as oncogene in some cancers

Researchers at Mayo Clinic in Florida have found that a molecule long believed to be a beneficial tumor suppressor and thus a potential cancer drug target appears to act as an oncogene in some lethal brain tumors.

28 Oct 2010

BioNanomatrix nanoAnalyzer 1000 System to be introduced at ASHG Annual Meeting

BioNanomatrix, Inc., which is developing and commercializing breakthrough single-molecule genomic analysis technology, will introduce next month the nanoAnalyzer 1000 System at the American Society of Human Genetics (ASHG) Annual Meeting from November 2-6, 2010 in Washington, D.C.

28 Oct 2010

Scientists develop new imaging technique that can detect breast cancer treatment response

Cancer Research UK scientists have developed a new imaging technique that can show when breast cancer treatment is working, weeks before current methods. The research is published in the British Journal of Cancer today1 (Wednesday).

27 Oct 2010

Evotec, Apeiron Biologics enter collaboration

Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Further projects will be evaluated to potentially expand this cooperation in due course.

27 Oct 2010

Molecule News and Research

454 Life Sciences and DNA Electronics partner to develop high-throughput DNA sequencing system

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Mechanism of rogue cell killer discovered

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Compugen signs oncology research collaboration agreement with Seattle Genetics

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

Mechanism that controls embryonic development could also prevent cancer

Novel small molecule inhibitors may provide new therapy for colon cancer

New findings on Th17 cells pave way for human cancer treatment protocol

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Richmont establishes distribution of PURE's SDC-based IV-7 products in Middle East

Immune system may play a role in cancer therapies: Study

The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

Scientists suggest E-cadherin can function as oncogene in some cancers

BioNanomatrix nanoAnalyzer 1000 System to be introduced at ASHG Annual Meeting

Scientists develop new imaging technique that can detect breast cancer treatment response

Evotec, Apeiron Biologics enter collaboration

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News